Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • Monday
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth AgendaGlobeNewsWire • 12/19/24
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal ReboundSeeking Alpha • 12/18/24
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/17/24
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of FameGlobeNewsWire • 12/05/24
Tevogen Bio Prepares Organizational Readiness to Support Company's Growth StrategyGlobeNewsWire • 11/26/24
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company ValueGlobeNewsWire • 11/21/24
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business ModelGlobeNewsWire • 11/19/24
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly FinancialsGlobeNewsWire • 11/14/24
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly FinancialsGlobeNewsWire • 11/14/24
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued OperationsGlobeNewsWire • 11/08/24
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920GlobeNewsWire • 11/05/24
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient SupportGlobeNewsWire • 11/04/24
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing CostsGlobeNewsWire • 10/31/24
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the CompanyGlobeNewsWire • 10/29/24
Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 MillionGlobeNewsWire • 10/29/24
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder EquityGlobeNewsWire • 10/29/24
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic AreasGlobeNewsWire • 10/25/24
Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug DevelopmentGlobeNewsWire • 10/23/24
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This WeekGlobeNewsWire • 10/22/24
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 BillionGlobeNewsWire • 10/21/24
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming DaysGlobeNewsWire • 10/21/24
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming DaysGlobeNewsWire • 10/19/24
